ArticleMolecular therapy. Nucleic acids2019

A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein.

Hui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.